Pharma Stability: Insights, Guidelines, and Expertise
ICH Q1D: “Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products” provides detailed guidance on applying these strategies under well-justified conditions.
Click to read the full article.
Biologics are large, complex molecules prone to degradation through mechanisms such as aggregation, deamidation, oxidation, and fragmentation. These changes can compromise efficacy, safety, and immunogenicity — especially under improper storage or handling conditions.
Click to read the full article.
Stability testing is vital during tech transfers to ensure that the product maintains its quality, safety, and efficacy throughout its shelf life when produced at a new site or with updated equipment/processes.
Click to read the full article.
Stability testing often involves:
Click to read the full article.
According to ICH Q1A(R2), real-time stability studies should be conducted on a minimum of three primary batches to justify the proposed shelf life of a drug product or substance.
Click to read the full article.
The frequency of sample pulls in long-term stability studies influences the quality of trend data, the reliability of shelf-life projections, and compliance with ICH and local health authority expectations.
Click to read the full article.
Stability data, especially from accelerated studies, often contains subtle trends that require statistical evaluation to detect, understand, and predict degradation behavior. Statistical modeling ensures consistency, supports shelf life claims, and enables extrapolation — particularly when real-time data is incomplete.
Click to read the full article.
Stability studies evaluate how the quality of a pharmaceutical product varies with time under the influence of environmental factors such as temperature, humidity, and light. These evaluations rely on the accuracy and sensitivity of the analytical methods used to detect changes — especially degradation.
Click to read the full article.
Risk-based stability study design focuses on identifying and mitigating potential risks that could affect product quality, shelf life, and regulatory compliance. Rather than testing every variable exhaustively, resources are directed where the risk is highest.
Click to read the full article.
Sample size directly influences the quality and reliability of stability data. Too few samples may lead to inconclusive results or regulatory non-compliance. Too many samples can overwhelm storage capacity, consume QC resources, and inflate costs.
Click to read the full article.